FibroBiologics (FBLG) Return on Capital Employed (2024 - 2026)
FibroBiologics (FBLG) posted quarterly Return on Capital Employed of 354.39% for Q2 2026, up 59040.0% year-over-year from N/an in Q2 2025, and down 22.68% on a QoQ basis from 288.86% in Q1 2026.
FibroBiologics (FBLG) Return on Capital Employed (2024 - 2026) Analysis & Trends
FibroBiologics has reported Return on Capital Employed for 3 years, with the latest figure at 354.39% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 354.39%, up 59040.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 354.39% (up 59040.0% YoY), and the FY2025 annual result was 147.69%, up 82864.0% from the prior year.
- Return on Capital Employed fell to 354.39% in Q2 2026, from 288.86% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 424.21% in Q1 2024 and troughed at 47685.11% in Q2 2024.
- A 3-year average of 5201.25% and a median of 370.21% in 2025 frame the typical range for Return on Capital Employed.
- The largest YoY upside for Return on Capital Employed was 4674032 bps in 2025 against a maximum downside of 68308 bps in 2025.
- A 3-year view of Return on Capital Employed shows it stood at 1879.34% in 2024, then jumped by 88 bps to 224.3% in 2025, then slumped by 58 bps to 354.39% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 354.39% in Q2 2026, 288.86% in Q1 2026, and 224.3% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | -354.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -354.39% |
| Mar 31, 2026 | -288.86% |
| Dec 31, 2025 | -224.30% |
| Sep 30, 2025 | -386.03% |
| Jun 30, 2025 | -944.79% |
| Mar 31, 2025 | -258.87% |
| Dec 31, 2024 | -1,879.34% |
| Sep 30, 2024 | -415.00% |
| Jun 30, 2024 | -47,685.11% |
| Mar 31, 2024 | 424.21% |